Full approval of Vitrakvi was based on results from three clinical trials in patients with unresectable or metastatic NTRK ...

Investment is expected to bring approximately 1,000 new jobs at Novartis and 4,000 additional roles across the United States.

In the Phase III ICONIC-LEAD trial, 75% of adolescents with moderate-to-severe plaque psoriasis treated with icotrokinra ...

Financing of Merida Biosciences was backed by Bain Capital Life Sciences, BVF Partners and Third Rock Ventures, with ...

As the physical products we use evolve to become increasingly complex, traditional products liability frameworks may not ...

Davidi Vortman, CEO, UltraSight, discusses how AI-powered heart scan technology can help high-risk cardiovascular disease ...

PharmaLogic states that the acquisition of Agilera Pharma AS will place the company in a unique global role in ...

Approval of the Opdivo plus Yervoy combination regimen was based on results from the Phase III CheckMate-8HW trial, which was ...

Hanadie Yousef, PhD, co-founder and CEO of Juvena Therapeutics, discusses Juvena’s "pipeline in a product" JUV-161 and plans to broaden into other disease indications.

The survey also suggests that Medicaid is broadly popular amongst all Americans, regardless of political affiliation.

Rahman discusses Google Gemini and what it could mean to the future of pharma commercialization and content development.

Results from Phase II studies demonstrated that rilzabrutinib showed clinically meaningful outcomes in patients with warm ...